comparemela.com

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

Related Keywords

Spain ,Madrid ,Spanish ,Antonio Gonzalez Martin ,Cancer Center Cl ,Spanish Ovarian Cancer Group ,Universidad De Navarra ,News ,Ovarian Cancer ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.